Title : Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

Pub. Date : 2013 Feb 1

PMID : 23169517






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 PURPOSE: Cabozantinib (XL184) is an orally bioavailable tyrosine kinase inhibitor with activity against MET and vascular endothelial growth factor receptor 2. cabozantinib kinase insert domain receptor Homo sapiens
2 PURPOSE: Cabozantinib (XL184) is an orally bioavailable tyrosine kinase inhibitor with activity against MET and vascular endothelial growth factor receptor 2. cabozantinib kinase insert domain receptor Homo sapiens